Navigation Links
Pharmaceutical Leak Testing Practices challenged by SEPHA
Date:5/4/2010

Leading packaging machinery manufacturer, Sepha, is challenging traditional thinking on leak testing procedures through the roll-out of a global Summer seminar and exhibition programme that will demonstrate how its new leak-testing technology can increase competiveness and revolutionise current packaging test methods within the pharmaceutical industry.

Belfast (Vocus) May 5, 2010 -- Package integrity is key to product quality and with excellence in quality and efficiency standards a major talking point within the Pharma industry today, Sepha’s state-of-the-art non-destructive leaking testing machines provide a technical, cost effective and objective blue-dye test alternative that does not compromise the product or the packaging.

Sepha is challenging traditional thinking on leak testing procedures through the roll-out of a global Summer seminar and exhibition programme that will demonstrate how its new leak-testing technology can increase competiveness and revolutionise current packaging test methods within the pharmaceutical industry.

“It is vital to ensure pharmaceutical product is fit for purpose at point of use. If compromised it can be become ineffective. The time honoured and widely used, global method of leak testing packaged product is the Methylene blue dye test. It is a messy, destructive and subjective test that really does not befit the technical excellence associated with modern pharmaceutical manufacturing. The subjective nature of this test and variance in set-up across packaging lines can lead to validation issues. This results in needless destruction of good packs and an intensive reliance on the operator.” explains Sepha Product Manager, Phil Stevenson.

Sepha has developed fully validatable alternatives to the Methylene Blue Dye test. For sachets and pouches PakScan is a machine that tests multiple packs using load cells to measure the force generated by the packaging under vacuum. PakScan machines are designed to isolate this force, measuring peak force and rate of change to establish presence of both large and small holes down to 10 micron.

For blister packs, which require multiple load cells for a single pack constraining machine capacity, flexibility and ease of calibration, Sepha has developed Blisterscan. This utilises a single laser to move across the blister pockets measuring their deflection and enhancing these changes by altering the pressure levels during testing. This system allows multiple packs to be tested in a single test making the blue dye test methodology obsolete.

Along with the cost benefits BlisterScan and PakScan provide they also produce useful batch data that can be used by manufacturers to monitor their performance and improve their line efficiencies.

“The real cost of running the Blue Dye Test is seen only when the cost of disposing the waste (financial and environmental) and lost production is considered. For example one packaging line producing 14 tablet blisters running two 8 hour shifts would waste $4480 per day based on the tablets costing $1 each and 10 packs being tested every half an hour. This cost is before disposal of tested product is even considered,” continues Phil.

When analysing quality and efficiencies on the production line, manufacturers must weigh up the cost-benefits of leak testing. For up and coming pharmaceutical companies seeking regulatory approval, Sepha’s non-destructive leak testing machines provide a means of proving quality standards whilst at the same time reducing costs.

Sepha will have its range of machines available at Pharmintech Italy, Total Process UK and Interphex Japan. They will also be holding a specialist seminar with over 100 leading players from Brazil’s Pharma industry in May. To find out more or to attend these seminars and expo’s please contact Sepha.

###

Read the full story at http://www.prweb.com/releases/2010/Sepha/prweb3959584.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
2. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
3. Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan
4. Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
5. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
6. HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry
7. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
10. ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress
11. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pharmaceutical Leak Testing Practices challenged by SEPHA
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
Breaking Biology Technology:
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
Breaking Biology News(10 mins):